EULAR 2021 – Day 1 Report
After the opening ceremonies and keynote speaker there were several enticing sessions and a plenary session full of great research and presentations. Here are a few of the highlights that I saw.
News
EULAR 2021 - Day 1 Podcasts
Check out this compilation of our EULAR 2021 Day 1 broadcasts below.
You can follow the EULAR 2021 RheumNow podcasts on iTunes and Soundclound.com
Listen by Clicking below:
EULAR 2021 - Opening Day
RheumNow has begun covering EULAR 2021, the premier Rheumatology Congress that is usually held in Europe, but has gone virtual in 2021 because of the pandemic. We have several faculty members around the world reporting on the this year's meeting. Please visit RheumNow.com daily for the latest videos, tweet summaries, news articles and podcasts emanating from EULAR. Look for our coverage on these and other important topics:
Featured Abstracts from Industry at EULAR 2021
Many great presentations this week at EULAR 2021 will feature industry sponsored clinical trials and reports. Often these become the pivotal studies for regulatory approval and the annual congresses are their first look.
Foot Pain Commonly Overlooked in RA
MedPage Today
Foot pain is a common but underappreciated symptom of rheumatoid arthritis (RA) and can be associated with worse disease, European researchers found.
Best Interventions for Gout Flares
A recent metanalysis assessed the comparative efficacy of current first-line pharmacologic antiinflammatory interventions for gout flares and surmised that canakinumab and intravenous or intramuscular corticosteroids are superior to nonsteroidal antiinflammatory drugs [NSAIDs].
COLCORONA: Protective Effect of Colchicine in COVID-19
Lancet Respiratory Medicine has reported the results of the COLCORONA trial, showing that in patients with PCR-confirmed COVID-19 infection, colchicine led to a significantly lower rate of death or hospital admission from COVID.
RheumNow Podcast – Heart, Lung & Liver (5.28.2021)
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.
Methotrexate Impairs COVID Vax Response
MedPage Today
One-third of patients with immune-mediated inflammatory diseases being treated with methotrexate showed attenuated responses to the COVID-19 vaccine, researchers reported.
Efficacy of 6 Weeks Antibiotics with Prosthetic Joint Infections
The NEJM has published the results of a French multicenter study showing that prosthetic joint infections can be successfully managed with 6 weeks of antibiotic therapy; this was noninferior and had better outcomes compared to 12 weeks of antibiotic therapy.
EULAR Guidelines on Intraarticular Therapy
EULAR has published evidence-based recommendations on the use of intra-articular therapies (IAT) based on the literature review and recommendations of a multidisciplinary international task force. These IAT recommendations apply to adult patients with peripheral arthropathies.
Triple DMARD Therapy Bested by Biologics in Swedish Registry
The Swedish Register compared outcomes of 1502 rheumatoid arthritis (RA) patients initiating either biologics plus methotrexate (MTX) or triple therapy (MTX plus sulfasalazine plus hydroxychloroquine/chloroquine) and showed similar rates of sustained remission.
